摘要
目的探讨在ⅠB-ⅡA期宫颈癌术后化疗后具有高危因素的患者放疗中使用顺铂增敏化疗是否对远期生存率有影响。方法将114例接受宫颈癌根治术并在术后进行2～3周期PF方案化疗的具有高危因素的ⅠB-ⅡA期宫颈癌患者分为两组:即在术后放疗中使用顺铂周次增敏化疗组(A组)和未使用顺铂周次增敏化疗组(B组),分别进行回顾性生存分析。结果 A、B两组5年无病生存率分别是66.2%±6.2%、53.3%±7.2%,5年总生存率分别是48.0%±6.1%、55.5%±7.2%。A、B两个治疗组在无病生存率和总生存率相比均有统计学差异(P=0.012;P=0.048)。结论ⅠB-ⅡA期宫颈癌术后化疗后具有高危因素的患者在放疗时同步行顺铂周次化疗可以起到增敏的作用并可提高远期生存率。
Objective To investigate that whether utilizing cisplatin in sensitization to the radiotherapy of high-risk patient after the chemotherapy of stage ⅠB-Ⅱ A radical surgery would have an impact on the long-term survival rate.Methods One hundred and fourteen high-risk stage ⅠB-Ⅱ A patients who have undergone radical surgery for cervical cancer and the 2 ～3 sessions of post-surgery PF programs for chemotherapy were selected and devided into two groups：Those who underwent weekly cisplatin in sensitization in the radiotherapy after their surgery （group A） and those who didn＇t （group B）.Results The 5-year disease-free survival （DFS） of group A and group B were 66.2％ ±6.2％,53.3％ ±7.2％,respectively.The 5-year overall survival （OS） of group A and group B were 68.0％ ±6.1％,55.5％ ±7.2％,respectively.Two groups had statistical significance in DFS and OS （P =0.012 ＜ 0.05; P =0.048 ＜ 0.05）.Conclusion Utilizing cisplatin weekly in the cheotherapy combined with radiotherapy after stage ⅠB-Ⅱ A surgery would enable sensitization and improve the long-term survival rate of cervical cancer.
出处
《哈尔滨医科大学学报》
CAS
北大核心
2013年第3期275-277,共3页
Journal of Harbin Medical University
基金
哈尔滨市科技创新人才研究专项资金项目(2011RFQYS079)
关键词
宫颈癌
放射治疗
顺铂
增敏化疗
远期生存率
cervical cancer
radiation therapy
cisplatin
sensitization to chemotherapy
long-term survival
